Stryker Corporation (SYK) shares fell to a 52-week low of $280.99, with the latest price data showing $280.58. The medical device maker, valued at about $108 billion, has declined 22% over the past year. The stock's weakness comes despite a Piotroski score of 9, a metric indicating strong financial health.
In its second-quarter 2026 results, Stryker reported adjusted earnings per share of $3.69, above Wall Street estimates of $3.49 and up 18% year over year. Revenue was $6.6 billion, compared with estimates of $6.58 billion, reflecting 9% organic revenue growth. The company said sales recovered after a cybersecurity incident earlier in the year, although investors remain cautious about the narrow full-year outlook and execution risks in the second half.
Stryker raised the low end of its fiscal 2026 organic growth guidance by 30 basis points and increased earnings per share guidance by $0.05.
Analyst reactions were mixed. Wolfe Research raised its price target to $375 from $350 and maintained an Outperform rating. Citizens lowered its target to $400 from $440 while keeping a Market Outperform rating, citing operational challenges in the first half of fiscal 2026, including a cyberattack and supply chain disruptions.
